newsroom.csl

World-class $1bn vaccine and antivenom manufacturing facility opens in Melbourne

Melbourne, Tuesday 2 December 2025 – Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing, opened CSL ...
newsroom.csl

CSL to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies

Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states KING OF PRUSSIA, PA, USA – November 18, 2025 — Global biopharma leader CSL (ASX:CSL; ...
newsroom.csl

CSL Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic ...

Thursday 30 October, Riyadh – CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by ...
newsroom.csl

Global Newsroom

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The University... CSL ...
newsroom.csl

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Purpose-built to optimise the production of plasma-derived therapies for conditions such as immunodeficiencies, neurological disorders, and burns, the Broadmeadows facility combines cutting-edge ...
newsroom.csl

Enhanced Influenza Vaccines Provide Essential Protection for Older Adults: CSL Seqirus Presents New Evidence Supporting Broader Adoption Across Europe

Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role ...
newsroom.csl

CSL’s near-term emissions reduction targets validated by the SBTi

Melbourne, Australia – 17 October 2025 – CSL has announced that the Science Based Targets initiative (SBTi) has approved CSL’s near-term science-based emissions reduction targets. These are: CSL ...
newsroom.csl

CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy ...

OTTAWA, Ontario, Oct. 6, 2025 /PRNewswire/ -- CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian ...
newsroom.csl

CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s development of ...
newsroom.csl

CSL announces rise in full year net profit

MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant ...
newsroom.csl

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a ...
newsroom.csl

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

What this means in practice is that there is enough evidence to show that sparsentan provides benefits and value for money, so it can be used routinely if it is considered the most suitable treatment ...